NASDAQ:HCWB HCW Biologics (HCWB) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free HCWB Stock Alerts $1.02 -0.10 (-8.93%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$1.00▼$1.1050-Day Range$1.01▼$1.6852-Week Range$0.91▼$2.32Volume13,594 shsAverage Volume15,579 shsMarket Capitalization$38.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get HCW Biologics alerts: Email Address Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About HCW Biologics Stock (NASDAQ:HCWB)HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Read More HCWB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HCWB Stock News HeadlinesMay 15, 2024 | investorplace.comHCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024May 15, 2024 | marketwatch.comHCW Biologics Warns of Ability to Continue Operating Without Additional FundsMay 15, 2024 | markets.businessinsider.comHCW Biologics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | globenewswire.comHCW Biologics Reports First Quarter 2024 Financial Results and Business HighlightsApril 2, 2024 | investorplace.comHCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023April 1, 2024 | globenewswire.comHCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business HighlightsFebruary 24, 2024 | finance.yahoo.comRebecca Byam Bought 122% More Shares In HCW BiologicsJanuary 25, 2024 | finance.yahoo.comSeveral Insiders Invested In HCW Biologics Flagging Positive NewsNovember 17, 2023 | markets.businessinsider.comHCW Biologics Receives Buy Rating: Strong Financial Position and Promising Clinical Data Validate Investment OpportunityNovember 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: HCW Biologics (HCWB), Urogen Pharma (URGN)November 14, 2023 | finanznachrichten.deHCW Biologics, Inc: HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business HighlightsNovember 14, 2023 | msn.comHCW Biologics GAAP EPS of -$0.14, revenue of $174.77MNovember 14, 2023 | finance.yahoo.comHCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business HighlightsNovember 11, 2023 | morningstar.comADMA Biologics Inc ADMANovember 11, 2023 | morningstar.comHCW Biologics Inc HCWBNovember 11, 2023 | markets.businessinsider.comPromising Phase 1 Results and Potential Synergies with PD-1 Inhibitors Bolster Buy Rating for HCW BiologicsNovember 8, 2023 | finance.yahoo.comInvestigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual MeetingNovember 6, 2023 | finance.yahoo.comSamsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma's portfolio companiesNovember 1, 2023 | finance.yahoo.comMasonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual MeetingSeptember 21, 2023 | seekingalpha.comHCW Biologics director Gary Winer buys shares worth $3.3k - filingSeptember 16, 2023 | finance.yahoo.comInsider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics IncSeptember 9, 2023 | finance.yahoo.comInsider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics IncSeptember 6, 2023 | finance.yahoo.comHCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023August 18, 2023 | finance.yahoo.comInsider Stock Buying Reaches US$845k On HCW BiologicsAugust 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Cochlear Limited (OtherCHEOF)See More Headlines Receive HCWB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/17/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HCWB CUSIPN/A CIK1828673 Webwww.hcwbiologics.com Phone954-842-2024Fax954-842-2037Employees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,990,000.00 Net Margins-697.53% Pretax Margin-697.50% Return on Equity-146.76% Return on Assets-81.74% Debt Debt-to-Equity Ratio0.95 Current Ratio0.46 Quick Ratio0.46 Sales & Book Value Annual Sales$2.84 million Price / Sales13.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.37 per share Price / Book2.76Miscellaneous Outstanding Shares37,820,000Free Float18,949,000Market Cap$38.58 million OptionableNot Optionable Beta0.93 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Hing C. Wong Ph.D. (Age 70)Founder, CEO, Director & Secretary Comp: $421.05kMs. Rebecca Byam CPA (Age 68)M.B.A., Chief Financial Officer Comp: $297.08kDr. Peter Rhode Ph.D. (Age 66)Chief Scientific Officer & VP of Clinical Operations Comp: $248.57kMs. Nicole Valdivieso Esq.Vice President of Legal AffairsMs. Raquel Diaz M.S.Director of Human ResourcesMr. Lee D. Flowers (Age 78)Senior Vice President of Business Development More ExecutivesKey CompetitorsT2 BiosystemsNASDAQ:TTOOEnlivex TherapeuticsNASDAQ:ENLVLiminal BioSciencesNASDAQ:LMNLSigilon TherapeuticsNASDAQ:SGTXCelyad OncologyNASDAQ:CYADView All CompetitorsInsiders & InstitutionsPullen Investment Management LLCBought 85,116 shares on 5/2/2024Ownership: 0.225%Hing C WongBought 1,800 shares on 9/14/2023Total: $3,744.00 ($2.08/share)Rebecca ByamBought 5,000 shares on 9/13/2023Total: $10,500.00 ($2.10/share)Gary M WinerBought 546 shares on 9/13/2023Total: $1,119.30 ($2.05/share)Rebecca ByamBought 5,000 shares on 9/11/2023Total: $10,250.00 ($2.05/share)View All Insider TransactionsView All Institutional Transactions HCWB Stock Analysis - Frequently Asked Questions How have HCWB shares performed in 2024? HCW Biologics' stock was trading at $1.2250 at the beginning of 2024. Since then, HCWB stock has decreased by 16.7% and is now trading at $1.02. View the best growth stocks for 2024 here. Are investors shorting HCW Biologics? HCW Biologics saw a decrease in short interest in May. As of May 31st, there was short interest totaling 1,200 shares, a decrease of 7.7% from the May 15th total of 1,300 shares. Based on an average daily volume of 17,700 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company's stock are short sold. View HCW Biologics' Short Interest. When is HCW Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our HCWB earnings forecast. How were HCW Biologics' earnings last quarter? HCW Biologics Inc. (NASDAQ:HCWB) announced its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $1.13 million for the quarter. HCW Biologics had a negative trailing twelve-month return on equity of 146.76% and a negative net margin of 697.53%. When did HCW Biologics IPO? HCW Biologics (HCWB) raised $45 million in an IPO on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton acted as the underwriter for the IPO and Revere Securities was co-manager. Who are HCW Biologics' major shareholders? HCW Biologics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pullen Investment Management LLC (0.23%). Insiders that own company stock include Gary M Winer, Hing C Wong, Jin-An Jiao, Lee Flowers, Rebecca Byam and Rick S Greene. View institutional ownership trends. How do I buy shares of HCW Biologics? Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HCWB) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.